Abstract:Neuropathic pain can result from injury to, or disease of the nervous system. It is notoriously difficult to treat. Peripheral nerve injury promotes Schwann cell activation and invasion of immunocompetent cells into the site of injury, spinal cord and higher sensory structures such as thalamus and cingulate and sensory cortices. Various cytokines, chemokines, growth factors, monoamines and neuropeptides effect two-way signalling between neurons, glia and immune cells. This promotes sustained hyperexcitability and spontaneous activity in primary afferents that is crucial for onset and persistence of pain as well as misprocessing of sensory information in the spinal cord and supraspinal structures. Much of the current understanding of pain aetiology and identification of drug targets derives from studies of the consequences of peripheral nerve injury in rodent models. Although a vast amount of information has been forthcoming, the translation of this information into the clinical arena has been minimal. Few, if any, major therapeutic approaches have appeared since the mid 1990's. This may reflect failure to recognise differences in pain processing in males vs. females, differences in cellular responses to different types of injury and differences in pain processing in humans vs. animals. Basic science and clinical approaches which seek to bridge this knowledge gap include better assessment of pain in animal models, use of pain models which better emulate human disease, and stratification of human pain phenotypes according to quantitative assessment of signs and symptoms of disease. This can lead to more personalized and effective treatments for individual patients. Significance statement: There is an urgent need to find new treatments for neuropathic pain. Although classical animal models have revealed essential features of pain aetiology such as peripheral and central sensitization and some of the molecular and cellular mechanisms involved, they do not adequately model the multiplicity of disease states or injuries that may bring forth neuropathic pain in the clinic. This review seeks to integrate information from the multiplicity of disciplines that seek to understand neuropathic pain; including immunology, cell biology, electrophysiology and biophysics, anatomy, cell biology, neurology, molecular biology, pharmacology and behavioral science. Beyond this, it underlines ongoing refinements in basic science and clinical practice that will engender improved approaches to pain management.

Neuropathic pain: Definition, classification and treatment

Neuropathic Pain: From Mechanisms to Treatment

Pharmacologic and Nonpharmacologic Management of Neuropathic Pain

Neuropathic pain: diagnosis and treatment

Neuropathic Pain Management, Pharmacological Approaches, Neuromodulation and Quality of Life

[Therapeutic advances in pharmaceutical treatment of neuropathic pain]

Central Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies

Neuropathic pain: Evidence based recommendations

Neuropathic pain; what we know and what we should do about it

Guideline “diagnosis and non interventional therapy of neuropathic pain” of the German Society of Neurology (deutsche Gesellschaft für Neurologie)

Neuropathic Pain: Mechanism, Representation, Management and Treatment

Spinal cord injury pain: mechanisms and management

Pharmacotherapy and noninvasive neurostimulation for neuropathic pain

Neuropharmacology of Neuropathic Pain: A Systematic Review

Neuropathic Pain Related to Peripheral Neuropathies According to the IASP Grading System Criteria

Neuromodulation for Neuropathic Pain Syndromes

Interventional Therapy for Neuropathic Pain

Novel Therapies for the Treatment of Neuropathic Pain: Potential and Pitfalls

[Chronic Pain: Definition/Conception/Classification of Pain].

An overview of the non‐procedural treatment options for peripheral neuropathic pain

The IASP classification of chronic pain for ICD-11: chronic neuropathic pain